Signalling pathways that mediate skeletal muscle hypertrophy and atrophy

@article{Glass2003SignallingPT,
  title={Signalling pathways that mediate skeletal muscle hypertrophy and atrophy},
  author={David J. Glass},
  journal={Nature Cell Biology},
  year={2003},
  volume={5},
  pages={87-90}
}
  • D. Glass
  • Published 1 February 2003
  • Medicine
  • Nature Cell Biology
Atrophy of skeletal muscle is a serious consequence of numerous diseases, including cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. This perspective will focus on the signalling pathways that control skeletal muscle atrophy and hypertrophy, including the recently identified ubiquitin ligases muscle RING finger 1 (MuRF1… Expand
Molecular mechanisms modulating muscle mass.
  • D. Glass
  • Biology, Medicine
  • Trends in molecular medicine
  • 2003
TLDR
A second strategy for blocking atrophy involves the stimulation of pathways leading to skeletal muscle hypertrophy, and the expression of two recently identified genes encoding ubiquitin-protein ligases, MAFbx/Atrogin-1 and MuRF1, has been shown to increase during muscle atrophy. Expand
Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy
TLDR
It is demonstrated that acute activation of Akt is sufficient to induce rapid and significant skeletal muscle hypertrophy in vivo, accompanied by activation of the downstream Akt/p70S6 kinase protein synthesis pathway. Expand
Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy
TLDR
The results show that the STARS signalling pathway is responsive to changes in skeletal muscle loading and appears to play a role in both human skeletal muscle hypertrophy and atrophy. Expand
The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy.
TLDR
The article identifies several inconsistencies between published human studies and data obtained from animal models of muscle atrophy, highlighting the need for a more comprehensive examination of the molecular events responsible for modulating muscle mass in humans. Expand
cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.
TLDR
This review concludes that sustained activation of cAMP signaling leads to pronounced hypertrophic responses in skeletal myofibers through largely elusive molecular mechanisms and should be harnessed to promote muscle regeneration in patients with acute damage or muscular dystrophy. Expand
Molecular and cellular mechanisms of skeletal muscle atrophy: an update
TLDR
The multifacetted therapeutic approach that is currently employed to prevent the development of muscle wasting and to counteract its progression is focused on, which includes adequate nutritional support, implementation of exercise training, and possible pharmacological compounds. Expand
- Mediated Muscle Atrophy in Chronic Left-Ventricular Dysfunction Transgenic Overexpression of Locally Acting Insulin-Like Growth Factor-1 Inhibits
Metabolic abnormalities develop in various chronic diseases and lead to progressive catabolism with decrements in the skeletal musculature that result in muscle atrophy. We investigated pathways ofExpand
Regulation of Muscle Protein Synthesis and Degradation in Normal and Pathophysiological States
Skeletal muscle is the most abundant tissue in the human body. Its mass is controlled through a delicate balance of signaling pathways that stimulate anabolism or hypertrophy of muscle cells throughExpand
Transgenic Overexpression of Locally Acting Insulin-Like Growth Factor-1 Inhibits Ubiquitin-Mediated Muscle Atrophy in Chronic Left-Ventricular Dysfunction
TLDR
The inhibition of Muscle atrophy by local insulin-like growth factor-1 provides a promising therapeutic avenue for the prevention of skeletal muscle wasting in chronic heart failure and potentially other chronic diseases associated with skeletal muscle atrophy. Expand
Atrophy and hypertrophy of skeletal muscles: structural and functional aspects
TLDR
An understanding of the specific modifications that occur during muscle atrophy and hypertrophy may facilitate the development of novel techniques, as well as new therapies for affected muscles. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
TLDR
It is concluded that the activation of the Akt/mTOR pathway and its downstream targets, p70S6K and PHAS-1/4E-BP1, is requisitely involved in regulating skeletal muscle fibre size, and that activation of this pathway can oppose muscle atrophy induced by disuse. Expand
Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy
TLDR
Two genes encode ubiquitin ligases that are potential drug targets for the treatment of muscle atrophy, and mice deficient in either MAFbx orMuRF1 were found to be resistant to atrophy. Expand
A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification
TLDR
It is reported that constitutively active protein kinase B (PKB), also known as Akt, increases fiber size and prevents denervation atrophy in regenerating and adult rat muscles but does not affect fiber type profile. Expand
Calcineurin Is Required for Skeletal Muscle Hypertrophy*
TLDR
Administration of the specific calcineurin inhibitors cyclosporin (CsA) or FK506 to mice prevented the rapid doubling of mass and individual fiber size and the 4–20-fold increase in the number of slow fibers that characterize this condition. Expand
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle
TLDR
A model of persistent, functional myocyte hypertrophy is generated using a tissue-restricted transgene encoding a locally acting isoform of insulin-like growth factor-1 that is expressed in skeletal muscle (mIgf-1) and suggests clinical strategies for the treatment of age or disease-related muscle frailty. Expand
IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1
TLDR
It is shown that the molecular pathways underlying the hypertrophic action of IGF-1 in skeletal muscle are similar to those responsible for cardiac hypertrophy. Expand
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
TLDR
It is shown that Akt promotes hypertrophy by activating downstream signalling pathways previously implicated in activating protein synthesis: the pathways downstream of mammalian target of rapamycin (mTOR) and the pathway activated by phosphorylating and thereby inhibiting glycogen synthase kinase 3 (GSK3). Expand
Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway
TLDR
It is proposed that growth-factor-induced skeletal-muscle hypertrophy and changes in myofibre phenotype are mediated by calcium mobilization and are critically regulated by the calcineurin/NF-ATc1 signalling pathway. Expand
Ras is involved in nerve-activity-dependent regulation of muscle genes
TLDR
It is shown that constitutively active Ras and a Ras mutant that selectively activates the MAPK(ERK) pathway are able to mimic the effects of slow motor neurons on expression of myosin genes, indicating that Ras–MAPK signalling is involved in promoting nerve-activity-dependent differentiation of slow muscle fibres in vivo. Expand
Stimulation of Slow Skeletal Muscle Fiber Gene Expression by Calcineurin in Vivo *
TLDR
It is demonstrated that calcineurin activation is sufficient to induce the slow fiber gene regulatory program in vivo and suggest that additional signals are required for skeletal muscle hypertrophy. Expand
...
1
2
3
4
5
...